Showing 6411-6420 of 6635 results for "".
- ADCS Clinics Acquires Additional Practicehttps://practicaldermatology.com/news/20121010-adcs_clinics_acquires_additional_practice/2459710/Less than a week after announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of Winter Park Dermatology. The practice is located in Wint
- Celgene to Present Data From Abraxane Melanoma Studyhttps://practicaldermatology.com/news/20121009-celgene_to_present_data_from_abraxane_melanoma_study/2459712/Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-fre
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Aesthetics Course Offers Cosmetic Practitioners Practical Business Advicehttps://practicaldermatology.com/news/20121002-aesthetics_course_offers_cosmetic_practitioners_practical_business_advice/2459724/Registration is now open for “Mastering the Business of Aesthetics” (MBA), a one-day course that teaches vital lessons regarding the financial components of cosmetic practice. The course will take place in Beverly Hills, CA on October 27th and cover topics such as optimizing laser business, increasi
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi